Rapport Therapeutics, Inc. Share Price
NASDAQ: RAPP | Small CapRapport Therapeutics, Inc. Stock Performance
Open $45.70 | Prev. Close $45.45 | Circuit Range N/A |
Day Range $45.52 - $47.10 | Year Range $13.94 - $47.40 | Volume 21,209 |
Average Traded $46.31 |
Rapport Therapeutics, Inc. Share Price Today
As of 11 August 2026, Rapport Therapeutics, Inc.'s share price is $46.95. The stock opened at $45.70, compared to its previous close of $45.45. During today's trading session, Rapport Therapeutics, Inc.'s share price traded between $45.52 and $47.10, with an average price of $46.31. Over the past 52 weeks, the stock has recorded a high of $47.40 and a low of $13.94. In terms of performance, Rapport Therapeutics, Inc.'s share price has risen by 62.01% over the last six months and is up 166.31% on a year-on-year basis.
Rapport Therapeutics, Inc. Share Price Chart
Rapport Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.83B | PE Ratio (TTM) -16.42 | Dividend Yield N/A |
EPS (TTM) $-2.86 | Revenue (TTM) N/A | Return On Equity (TTM) -23.00% |
Profit Margin N/A | Debt to Equity 0.04 | Quarterly Earnings Growth YoY -53.53% |
Rapport Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Rapport Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Rapport Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $40.13 | $46.95 | +14.36% |
Jul 2026 | $41.12 | $41.06 | -1.65% |
Jun 2026 | $37.98 | $41.75 | +5.72% |
May 2026 | $32.84 | $39.49 | +19.09% |
Apr 2026 | $31.58 | $33.16 | +5.40% |
Mar 2026 | $28.41 | $31.46 | +8.56% |
Feb 2026 | $26.99 | $28.98 | +8.99% |
Jan 2026 | $30.08 | $26.59 | -12.40% |
Dec 2025 | $28.92 | $30.36 | +2.48% |
Nov 2025 | $29.13 | $29.62 | +2.51% |
Oct 2025 | $30.43 | $28.89 | -3.00% |
Sep 2025 | $17.41 | $29.79 | +68.97% |
RAPP Share Price FAQs
What is Rapport Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Rapport Therapeutics, Inc. stock?
What is RAPP's market capitalisation today?
What is RAPP's net income for the last quarter?
What is the 5 year returns of RAPP?
What is the high & low stock price of RAPP today?
Can I buy RAPP shares in India?